Results 181 to 185 of about 1,288 (185)

Ibrexafungerp. 1,3-Beta-Glucan synthase inhibitor, Triterpenoid antifungal agent

Drugs of the Future, 2019
null Thakare, R., null Dasgupta, A., null Chopra, S.   +2 more
openaire   +1 more source

Estimated time to relief from vulvovaginal symptoms with ibrexafungerp: patient reported data from the VANISH studies

American Journal of Obstetrics and Gynecology, 2023
Azie N, King T, Sanchez S, Angulo D
openaire   +1 more source

Ibrexafungerp (Brexafemme) for vulvovaginal candidiasis.

The Medical letter on drugs and therapeutics, 2021
openaire   +1 more source

Methodologic and analytic considerations in the CANDLE trial of ibrexafungerp for recurrent vulvovaginal candidiasis (Letter-to-the-Editor).

American Journal of Obstetrics and Gynecology
M. Azizi, Zeinab Sinaeifar
semanticscholar   +1 more source

Methodologic and analytic considerations in the CANDLE trial of ibrexafungerp for recurrent vulvovaginal candidiasis (Reply to Letter-to-the-Editor).

American Journal of Obstetrics and Gynecology
Oluwatosin Goje, P. Nyirjesy, Jack D. Sobel   +2 more
semanticscholar   +1 more source